Traitements6programmes
Essais3liés
Publications26liées
SourceDBlocale

Traitements

6
MoléculeIndication / populationPhaseObjectifPaysRésultat
ALLO-329This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to evaluate the safety and tolerability of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune disorders, provide initial evidence of biological activity and clinical response to the treatment and determine the recommended Phase 2 regimen (RP2R). Lupus, Myopathies Phase 1 Immunomodulation + Thérapie cellulaire United States, Canada À vérifier
CyclophosphamideThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Cancer, Épilepsie, Lupus, Myasthénie, Myopathies, SEP Phase 1 À vérifier United States, Canada À vérifier
FludarabineThe purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years. Cancer, Lupus, Myasthénie, Myopathies, SEP Phase 1 Immunomodulation + Thérapie cellulaire United States, Canada À vérifier
CyclophosphamideThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Lupus NA À vérifier Brazil À vérifier
ALLO-329This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to evaluate the safety and tolerability of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune disorders, provide initial evidence of biological activity and clinical response to the treatment and determine the recommended Phase 2 regimen (RP2R). Lupus Phase 1 Immunomodulation + Thérapie cellulaire United States, Canada À vérifier
CyclophosphamideThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Cancer Phase 2 Thérapie cellulaire United States À vérifier

Essais cliniques

3
MoléculeIndication / populationPhaseNCTTitreStatut
Cyclophosphamide Cancer Phase 2 NCT07524530 Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers NOT_YET_RECRUITING
ALLO-329 Lupus Phase 1 NCT07085104 RESOLUTION — A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease RECRUITING
Cyclophosphamide Lupus NA NCT03492255 CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid TERMINATED

Publications

26
MoléculeIndication / populationTitreJournalDate
Fludarabine Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma. Blood advances
Fludarabine Tailored conditioning for hematopoietic stem cell transplantation in children with Mendelian susceptibility to mycobacterial disease: A tale of two pathways for IFN-γ and IL-12 defects. Journal of human immunity
Fludarabine Targeting IMPDH to inhibit SAMHD1 in -rearranged leukaemia. Cell cycle (Georgetown, Tex.)
Cyclophosphamide A systematic assessment of the short- and long-term effects of commonly used breast cancer chemotherapeutics on the gut microbiome‒blood‒brain axis of female mice. Gut microbes
Cyclophosphamide Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR. Autoimmunity
Cyclophosphamide Multi-omics reveals the mechanism of Rehmannia glutinosa Libosch. Processed with Amomum villosum Lour. in treating blood deficiency syndrome. Journal of ethnopharmacology
Fludarabine A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation. Leukemia & lymphoma
Fludarabine The discovery of potent and selective N-modified adenosine derivatives as effective chemotherapeutic agents to overcome p53-dependent drug resistance in cancer and HPIV-3/AdV5 respiratory tract infections. Bioorganic chemistry
Cyclophosphamide SP-3 Ameliorates Established Cyclophosphamide-Induced Liver Injury and Is Associated with PPAR-Related Transcriptional and Lipid-Metabolic Changes. International journal of molecular sciences
Cyclophosphamide Amyloidosis and Thoracic Aortic Disease: A Scoping Review. Journal of clinical medicine
Cyclophosphamide [Sustained complete remission achieved with tofacitinib in a refractory T-cell large granular lymphocytic leukemia]. La Revue de medecine interne
Cyclophosphamide Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in sickle cell disease: a narrative review of safety, engraftment, and graft-versus-host-disease outcomes in adults and high-risk populations. Bone marrow transplantation
Cyclophosphamide Alleviation effect of Potentilla anserina polysaccharides on intestinal barrier dysfunction and its underlying mechanism. International journal of biological macromolecules
Cyclophosphamide Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study. British journal of haematology
Fludarabine Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia: A single - Arm prospective clinical trial. Cell transplantation
Cyclophosphamide Salvage ultra-low-dose radiotherapy for conjunctival mantle cell lymphoma - a case report and literature review. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Cyclophosphamide Application Timing-Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma. Hematological oncology
Cyclophosphamide Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Cyclophosphamide Multi-omics integration reveals that pterostilbene ameliorates cyclophosphamide-induced liver injury the gut-liver axis by inhibiting inflammation and oxidative stress. Food & function
Fludarabine Novel pathological genetic variant associated with DOCK8 deficiency: case report with successful hematopoietic stem cell transplantation. Allergologia et immunopathologia
Fludarabine Precision myeloablation with TDM-guided busulfan in pediatric primary immunodeficiencies: a real-world study of 28 patients. Translational pediatrics
Cyclophosphamide Dermatomyositis With Necrotizing Vasculitis, Pulmonary Arterial Hypertension, and Extensive Calcinosis Following Delayed Diagnosis. Cureus
Fludarabine Radioimmunotherapy as a targeted strategy of reduced-intensity conditioning for allogeneic transplantation in leukemia. Frontiers in oncology
Fludarabine Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT. Bone marrow transplantation
Cyclophosphamide Refractory Malignant Pericardial Effusion as the Initial Presentation of Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. Cureus
Cyclophosphamide Incidence and impact of odontogenic infection-related febrile episodes during perioperative doxorubicin-cyclophosphamide or docetaxel-cyclophosphamide chemotherapy for breast cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer